Companies are failing to protect their products with tamper evidence but the EU falsified medicine directive, plus the ease of implementation, will drive adoption, according to a director at Schreiner ProSecure.
Thomas Voelcker, marketing and sales director at Schreiner ProSecure, explained that the current draft of European Union (EU) falsified medicine directive will drive adoption of some anti-counterfeiting measures.
Product authentication, tamper evidence and serialisation are included in the directive. Voelcker believes that the majority of big pharma companies have serialisation measures in place and some are adopting authentication systems on a risk-based approach.
However, companies are failing to protect their products with tamper evidence.